BSc (Hons), PhD
Professor of Matrix Biology
Professor Kim Midwood graduated with a B.Sc. (HONS) in Biochemistry from Edinburgh University in 1995. She completed her Ph.D. in the Department of Pathology at Edinburgh University in 1999, focusing on how changes in the extracellular matrix affect cellular signalling pathways in arthritis. She undertook postdoctoral training in the lab of Professor Jean Schwarzbauer, at Princeton University from 1999, continuing her work investigating the molecular mechanisms by which the cellular environment defines cell phenotype.
In 2004 she established the Matrix Immunology group in the Kennedy Institute of Rheumatology at Imperial College London, moving to Oxford University in 2011.
In 2007 she won an MRC New Investigators Award and in 2012 an Arthritis Research UK Senior Fellowship.
She founded the BioTech company Nascient Ltd in 2012..
Giblin SP. et al, (2020), Matrix Biol
Matrix-targeting immunotherapy controls tumor growth and spread by switching macrophage phenotype
MIDWOOD KIM., (2020), Cancer Immunology Research
Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis
Izadi D. et al, (2019), Science Advances
Tenascin-C: a driver of inflammatory bowel disease?
Ozanne J. et al, (2019), INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 100, A29 - A30
Alternative splicing of tenascin-C modulates cell-matrix interactions during inflammation and disease
(2019), MOLECULAR BIOLOGY OF THE CELL